Search Results
Your search for 3 matches 14941 pages
Showing 5351 - 5400American Cancer Society Updates Guideline for Cervical Cancer Screening
An updated cervical cancer screening guideline from the American Cancer Society has called for less—and more simplified—screening. The guideline was published by Elizabeth T.H. Fontham, MPH, DrPH, of Louisiana State University School of Public Health, New Orleans, and colleagues in CA: A Cancer...
Higher Risk of Disease Recurrence and Death With Minimally Invasive vs Open Surgery for Early-Stage Cervical Cancer
Women with early-stage cervical cancer treated with minimally invasive radical hysterectomy had a 71% increased risk of recurrence and a 56% increased risk of death compared with those treated with open radical hysterectomy, according to a systematic review and meta-analysis of 15 studies involving ...
Lenvatinib/Pembrolizumab in Previously Treated Patients With Advanced Endometrial Cancer
As reported in the Journal of Clinical Oncology by Vicky Makker, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues, findings from a phase Ib/II trial indicate that the combination of lenvatinib and pembrolizumab is active in patients with previously treated advanced...
Addition of Trastuzumab to Carboplatin/Paclitaxel for Advanced or Recurrent HER2-Positive Uterine Serous Carcinoma
Combining the HER2-targeted therapy trastuzumab with carboplatin and paclitaxel improved survival rates for women with a rare, aggressive type of endometrial cancer, according to findings published by Amanda N. Fader, MD, of Johns Hopkins School of Medicine, Baltimore, and colleagues in Clinical...
LACC Trial: Quality of Life With Open vs Minimally Invasive Radical Hysterectomy for Patients With Cervical Cancer
As reported in The Lancet Oncology by Michael Frumovitz, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues, there were no significant differences in quality of life, a secondary endpoint, for women undergoing open vs minimally invasive radical hysterectomy for...
PORTEC-3: Effect of Molecular Classification of Endometrial Cancer on Outcomes With Adjuvant Therapy
In a study reported in the Journal of Clinical Oncology, Alicia Léon-Castillo, MD, of Leiden University Medical Center, the Netherlands, and colleagues identified outcomes associated with molecular subgroups of patients with high-risk endometrial cancer enrolled in the PORTEC-3 trial of adjuvant...
SGO 2020: WEE1 Inhibitor Shows Activity in Recurrent Uterine Serous Carcinoma
Monotherapy with the experimental WEE1 inhibitor adavosertib has shown activity in patients with advanced recurrent or metastatic uterine serous carcinoma,1 according to data presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series. The initial ...
Expert Point of View: Nicoletta Colombo, MD
The invited discussant of the two trials in cervical and endometrial cancers presented at the ESMO Congress 2019 was Nicoletta Colombo, MD, of the University of Milan-Bicocca in Italy, who commented on what she called “exciting results in cancers with unmet needs.” Dr. Colombo noted: “The studies...
ESMO 2019: Immunotherapy in Cervical and Endometrial Cancers
In studies reported at the ESMO Congress 2019, immunotherapy yielded encouraging outcomes in two gynecologic cancer populations in need of new treatments, including patients with advanced cervical cancer that is microsatellite-stable and patients previously treated for advanced endometrial cancer....
SGO 2020: Updated Analysis of VELIA Trial Shows Antitumor Activity in Ovarian Cancer, but Is It Enough?
An updated analysis of the phase III VELIA/GOG-3005 trial, presented during the 2020 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer Webinar Series,1 suggested synergy between the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib and platinum chemotherapy in the...
ASCO20: Cediranib Plus Olaparib vs Standard-of-Care Chemotherapy for Platinum-Sensitive Ovarian Cancer
Results of the NRG Oncology phase III clinical trial NRG-GY004 indicated that the addition of the investigational agent cediranib to olaparib and standard platinum-based chemotherapy did not improve progression-free survival outcomes for women with platinum-sensitive ovarian cancer; however,...
KEYNOTE-100: In Women With Advanced Ovarian Cancer, Pembrolizumab Yields Modest Antitumor Efficacy
the final results of the phase II KEYNOTE-100 study of pembrolizumab in women with advanced and recurrent ovarian cancer showed that pembrolizumab monotherapy produced modest clinical activity. Ursula Matulonis, MD, of Dana-Farber Cancer Institute, Harvard Medical School, reported the data at the...
ASCO20: Final Overall Survival Analysis From SOLO2 in Ovarian Cancer
For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...
Expert Point of View: Robert L. Coleman, MD
Discussant of the DESKTOP III and SOC1 trials, Robert L. Coleman, MD, of U.S. Oncology Research in Woodlands, Texas, congratulated the authors of both trials. He put these results in perspective with the GOG-0213 study, which did not show a survival benefit for secondary surgery. “There are general ...
ASCO20: Secondary Surgery May Extend Survival in Recurrent Ovarian Cancer
Two phase III trials provided support for secondary cytoreductive surgery in women with recurrent ovarian cancer, with the caveats that patient selection is key and the surgery should be performed at sites of excellence. The results of the DESKTOP III and SOC1 trials, both presented during the...
ESMO 2019: Veliparib Plus First-Line Chemotherapy and as Maintenance Therapy in High-Grade Ovarian Cancer
In the phase III VELIA/GOG-3005 trial—reported at the European Society for Medical Oncology (ESMO) Congress 20191 and simultaneously published in The New England Journal of Medicine2—Robert L. Coleman, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues found that the ...
ESMO 2019: PRIMA Trial Reports Benefit With Niraparib Across Ovarian Cancer Subsets
In women with advanced ovarian cancer responding to first-line chemotherapy, maintenance therapy with the poly (ADP-ribose) polymerase (PARP) inhibitor niraparib significantly reduced the risk of disease progression by 38% overall and by 60% in women with BRCA mutations. Even patients without a...
Novel Drug Approvals and New Indications for Gynecologic Cancers
A number of new drugs and novel indications were added to the treatment armamentarium for gynecologic cancers over the past year. The U.S. Food and Drug Administration (FDA) approvals are noted here. Olaparib, PARP Inhibitor On May 8, 2020, the FDA expanded the indication of olaparib (Lynparza) to...
SGO 2020: Updated Data From PRIMA Trial: Niraparib as First-Line Maintenance Therapy for Advanced Ovarian Cancer
Making sense of maintenance therapy in advanced ovarian cancer has been a tall order since the publication of impressive data for not one but three poly (ADP-ribose) polymerase (PARP) inhibitors at the European Society for Medical Oncology (ESMO) 2019 Congress.1 The picture became a little clearer...
Clinical Perspective on PAOLA-1: Maintenance Therapy for Advanced Ovarian Cancer
Based on multiple phase III prospective trials, there is evidence that both poly (ADP-ribose) polymerase (PARP) inhibitors and antiangiogenic therapies such as bevacizumab provide benefit when utilized in a maintenance strategy in the first-line treatment of advanced epithelial ovarian cancer (GOG...
Addition of Olaparib to Bevacizumab Maintenance in Advanced Ovarian Cancer: PAOLA-1 Trial
As reported inThe New England Journal of Medicine by Isabelle Ray-Coquard, MD, PhD, of the Céntre Léon Berard, University Claude Bernard Lyon 1 and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Paris, and colleagues, the phase III PAOLA-1 trial has shown a...
Gynecologic Oncology Highlights 2019–2020 Almanac
Ovarian cancer is associated with the highest risk of mortality among the five most common gynecologic cancers (cervical, ovarian, uterine [endometrial], vaginal, and vulvar) in the United States; in 2020 in the United States, ovarian cancer will be diagnosed in an estimated 21,750 women, and...
Adjuvant Nivolumab Plus Ipilimumab vs Nivolumab Alone in Resected Stage IV Melanoma With No Evidence of Disease
In an interim analysis of the German phase II IMMUNED trial reported in The Lancet, Lisa Zimmer, MD, of University Hospital Essen, and colleagues found that adjuvant nivolumab plus ipilimumab and nivolumab alone significantly prolonged recurrence-free survival vs placebo in patients with resected...
Does Binimetinib Improve Progression-Free Survival in Recurrent or Persistent Low-Grade Serous Ovarian Carcinomas?
As reported in the Journal of Clinical Oncology by Bradley J. Monk, MD, and colleagues, the phase III MEK Inhibitor in Low-Grade Serous Ovarian Cancer (MILO)/ARRAY-162-311/ENGOT-ov11 trial showed that the MEK1/2 inhibitor binimetinib did not improve progression-free survival vs physician’s choice...
Addition of Veliparib to Carboplatin/Paclitaxel in Previously Treated Patients With BRCA-Mutated Advanced Breast Cancer: BROCADE3 Trial
As reported in The Lancet Oncology by Véronique Diéras, MD, and colleagues, the phase III BROCADE3 trial showed a significant improvement in progression-free survival with the addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to carboplatin and paclitaxel in patients with...
Comparing Pazopanib to Doxorubicin in Patients Aged 60 and Older With Soft-Tissue Sarcoma
Doxorubicin is a standard of care in patients with advanced inoperable soft-tissue sarcoma. In the EPAZ study, German researchers tested whether pazopanib showed comparable efficacy to doxorubicin in the first-line treatment of elderly patients with soft-tissue sarcoma. Grünwald et al reported in...
FDA Approves Oral Azacitidine as Maintenance Therapy for Adults With AML in First Remission
On September 1, the U.S. Food and Drug Administration (FDA) approved oral azacitidine (Onureg; also known as CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission or complete remission with incomplete blood count recovery...
Changes in Reoperation Rates After Publication of SSO/ASTRO Guideline on Margins for Breast-Conserving Surgery
In a meta-analysis reported in JAMA Surgery, Marinovich et al found that reoperation rates after breast-conserving surgery in women with breast cancer declined after the publication of the Society of Surgical Oncology/American Society for Radiation Oncology (SSO/ASTRO) Consensus Guideline on...
Is It Time to Add Checkpoint Inhibitors to the Treatment of Locally Advanced Lung Cancer?
After more than 20 years of failed strategies to improve survival rates for locally advanced lung cancers, checkpoint inhibitors have revolutionized therapy, but prognoses still lag behind other tumor types. During the ASCO20 Virtual Education Program, Mark G. Kris, MD, FASCO, a thoracic medical...
Assessment of Potential Abscopal Effect of SBRT Added to Nivolumab in Metastatic Head and Neck Cancer
In a single-center phase II trial reported in the Journal of Clinical Oncology, McBride et al found that use of stereotactic body radiotherapy (SBRT) for a potential abscopal effect together with nivolumab did not improve objective response rate vs nivolumab alone in patients with metastatic head...
Metastatic Prostate Cancer: Sorting Through the Treatment Maze
The message still needs to get out that metastatic castration-sensitive prostate cancer should be treated with both androgen-deprivation therapy (ADT) and either docetaxel or an androgen receptor pathway inhibitor. In spite of “overwhelming” support for ADT plus abiraterone/prednisone,...
Meta-analysis of FOLFOXIRI/Bevacizumab vs Doublets/Bevacizumab as Initial Treatment for Unresectable Metastatic Colorectal Cancer
In a patient-level meta-analysis reported in the Journal of Clinical Oncology, Chiara Cremolini, MD, PhD, and colleagues found that infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) plus bevacizumab was associated with significantly greater overall survival vs...
ORIENT-11 Trial Shows Sintilimab Plus Chemotherapy Improves Progression-Free Survival in Advanced NSCLC
The first-line setting for patients with locally advanced or metastatic non-squamous non–small cell lung cancer (NSCLC) now has become more complicated, according to data presented during the 2020 International Association for the Study of Lung Cancer’s World Conference on Lung Cancer Virtual...
Acupuncture vs Sham Procedure and Usual Care for Chemotherapy-Induced Peripheral Neuropathy
Chemotherapy-induced peripheral neuropathy is a debilitating and enduring adverse effect of many antineoplastic agents, which negatively impacts the quality of life of patients with cancer and survivors. Current pharmacotherapy has limited efficacy and causes undesirable effects. In this...
RET Inhibitor Selpercatinib Achieves Durable Responses in Majority of Patients With RET Gene Fusions
For patients with non–small cell lung cancers (NSCLC) marked by RET gene fusions, the targeted therapy selpercatinib was well tolerated and achieved durable objective responses in the majority of participants in the phase I/II LIBRETTO-001 trial, according to researchers from The University of...
Addition of Nelarabine to Standard Therapy in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia
As reported in the Journal of Clinical Oncology by Dunsmore et al, the phase III Children’s Oncology Group AALL0434 trial has shown that the addition of nelarabine to standard therapy improved disease-free survival in children and young adults with newly diagnosed T-cell acute lymphoblastic...
From Behind the Iron Curtain to a Career in Gynecologic Cancer Research for Daniela Matei, MD
Daniela Matei, MD, Diana, Princess of Wales Professor of Cancer Research at Northwestern Feinberg School of Medicine, Chicago, grew up Sibiu, a picturesque Romanian city situated at the foothills of the Cindrel Mountains in historic Transylvania. “Both of my parents were physicians, and some of my ...
Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naive and Relapsed or Refractory Chronic Lymphocytic Leukemia
In a single-institution phase II trial reported in the Journal of Clinical Oncology, Rogers et al found that the combination of obinutuzumab, ibrutinib, and venetoclax produced high response rates in both treatment-naive and relapsed or refractory chronic lymphocytic leukemia. Study Details A total ...
Gynecologic Cancer Advocate, Wendy Noelle Ericsson, Dies at Age 60
The Society of Gynecologic Oncology announced with sadness the death of Wendy Noelle Ericsson, an advocate and champion of the Foundation for Women’s Cancer, an advocacy group supporting research, education, and public awareness of gynecologic cancers. Ms. Ericsson’s death was due to complications...
One in Six Premenopausal Women With Invasive Breast Cancer Is Nonadherent to Tamoxifen Therapy
Measuring serum levels of tamoxifen among premenopausal women being treated for invasive breast cancer identified a “worryingly high proportion of patients, one in six, who were nonadherent to therapy at only 1 year after treatment prescription,” researchers reported in the Journal of Clinical...
Tumeur Fibro-Plastique
The text and photograph here are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, The Anesthesia Era 1845–1875 by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photograph appears courtesy of Stanley B. Burns, MD, and The Burns...
Ashwagandha
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. In this installment, Gary Deng, MD, PhD, and Jyothirmai Gubili, MS, present updated information on ...
Managing Cancer in Older Adults During the COVID-19 Pandemic
The COVID-19 pandemic is an additional competing risk to factor in when making decisions about anticancer treatment for older adults. It poses a potential barrier to equal and evidence-based management of cancer in this group of patients. Implementing geriatric assessments in routine clinical...
Association of Community Cancer Centers Announces 2020 Innovator Award Recipients
The Association of Community Cancer Centers (ACCC) announced the winning programs for its 10th annual ACCC Innovator Awards, highlighting the year’s leading-edge strategies to challenges faced by oncology programs and practices across the country. The eight ACCC Innovator Award winners feature...
How to Treat Patients With Multiple Myeloma Cost-Effectively Without Compromising Outcome
The dramatic advances in the diagnosis and treatment of multiple myeloma over the past 20 years have resulted in significant improvements in overall survival, with 5-year relative survival rates now around 50% and more than 60% for patients younger than age 70.1 The proteasome inhibitors...
How the First International Summit on Interventional Pharmacoeconomics Is Sparking Discussion on Reducing Cancer Costs
Three years ago, former Chief Executive Officer of ASCO, Allen S. Lichter, MD, Laurence H. Baker, DO, Professor in the Departments of Internal Medicine and Pharmacology at the University of Michigan Medical School in Ann Arbor; Leonard Saltz, MD, a gastrointestinal oncologist at Memorial Sloan...
For Your Patients: An Expert Q&A on Cancer Disparities and Health Equity
Cancer does not affect all people equally. The phrase “cancer disparities” refers to the differences in the number of new cancer cases as well as differences in cancer outcomes that exist among different populations. Disparities more often negatively affect racial and ethnic minorities, poor...
Final ASCEND Results Confirm Acalabrutinib as a Standard for Relapsed CLL
The Bruton’s tyrosine kinase (BTK) inhibitors have been one of the most exciting advances in the tre atment of chronic lymphocytic leukemia (CLL) and have led to the development of chemotherapy-free treatments for both treatment-naive as well as relapsed or refractory CLL based on studies where...
Acalabrutinib Improves Progression-Free Survival vs Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed or Refractory CLL
As reported in the Journal of Clinical Oncology by Paolo Ghia, MD, PhD, of the Università Vita-Salute San Raffaele, Milan, Italy, and colleagues, the phase III ASCEND trial showed significantly prolonged progression-free survival with acalabrutinib monotherapy vs the investigator’s choice of...
Adding Immunotherapy to BRAF/MEK Inhibition in BRAF V600–Mutant Melanoma: First Step on the Journey
As investigators, we were always determined to find the drug to work with BRAF/MEK inhibitor combination therapy. It had come on like a storm and showed us that we could help even those with the most advanced metastatic melanoma, as long as it harbored the magical BRAF V600E mutation.1...
